Oramed Pharmaceuticals Inc. (ORMP) Tops Q3 EPS by 19c

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) reported Q3 EPS of $0.15, $0.19 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $1.18 million.

For earnings history and earnings-related data on Oramed Pharmaceuticals Inc. (ORMP) click here.

You May Also Be Interested In

• Sinda opens at $10.80, IPO priced at $12
• Wendy's (WEN) call put ratio 3.5 calls to 1 put with a focus on 2800 contracts of July 9 calls
• Oppenheimer Reiterates Perform Rating on Acadia Pharmaceuticals (ACAD)